Last €79.00 EUR
Change Today +0.23 / 0.29%
Volume 11.6K
SANNV On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
EN Paris
Frankfurt
Frankfurt
NASDAQ GM
As of 11:00 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-new (SANNV) Snapshot

Open
€78.35
Previous Close
€78.77
Day High
€79.00
Day Low
€78.35
52 Week High
01/23/15 - €80.00
52 Week Low
01/6/15 - €70.35
Market Cap
--
Average Volume 10 Days
23.1K
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI-NEW (SANNV)

sanofi-new (SANNV) Details

Sanofi discovers, develops, and distributes therapeutic solutions. Its primary products include Lantus and Apidra analogs of human insulin; Insuman insulin solutions and suspensions; Amaryl, a sulfonylurea; Lyxumia, a prandial GLP-1 receptor agonist; BGStar, iBGStar, and MyStar Extra blood glucose meters; Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme for mucopolysaccharidosis Type I; Aubagio for multiple sclerosis; and Lemtrada, a humanized monoclonal antibody. The company’s products also comprise Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; Jevtana for prostate cancer; Thymoglobulin, an immuno-suppressive and immuno-modulating agent; Mozobil stem cell mobilizer; and Zaltrap recombinant fusion protein. In addition, it offers thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. Further, it provides Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements for pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has a strategic alliance with Illumina, Inc. to develop a next-generation sequencing based oncology test system. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1973

sanofi-new (SANNV) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2013.

sanofi-new (SANNV) Key Developments

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Praluent (Alirocumab) Biologics License Application acceptance by U.S. Food and Drug Administration for Review

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for PraluentTM (alirocumab). Under the Prescription Drug User Fee Act, the goal for a priority review is six months, for a target action date of July 24, 2015. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia. The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. Earlier this month, the companies announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for Praluent in the European Union. The EMA and FDA have conditionally accepted Praluent as the trade name for alirocumab. The safety and efficacy of alirocumab have not been fully evaluated by any regulatory authority.

VECT-HORUS Announces Signing of Scientific Collaboration Agreement with Sanofi

VECT-HORUS announced the signing of a scientific collaboration agreement with SANOFI. The goal of this collaboration is to use VECT-HORUS' proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease. The blood-brain barrier (BBB) restricts very effectively the passage of imaging or therapeutic agents from blood to brain. Effectiveness of this barrier increases with the size of the molecules and as a consequence, the vast majority of the innovative biomolecules developed by the pharmaceutical industry, including peptides, proteins, therapeutic antibodies, with promising potential in the field of brain disorders, do not cross the BBB. CNS diseases represent a high unmet medical need and already the second large therapeutic market, in spite of the fact that there is still no cure or efficient treatments to tackle neurodegenerative diseases. Transporting drugs across the BBB is thus a technological barrier that VECT-HORUS intends to lift, allowing thereby the treatment of neurodegenerative diseases, particularly with therapeutic antibodies. The scientific approach of the company is based on the principle that the BBB is not only a physical barrier that must be crossed, but also a functional barrier whose natural transport mechanisms may be advantageously used to deliver drugs into the brain. The peptide-vectors developed by VECT-HORUS use endogenous transport mechanisms to facilitate the passage of drugs or imaging agents across the BBB, into the pathological brain.

Sanofi, Boehringer Ingelheim Enter into Monoclonal Antibodies Partnership

Sanofi announced that it has sealed a strategic partnership with Boehringer Ingelheim to produce therapeutic monoclonal antibodies. The partnership is aimed at boosting Sanofi's manufacturing capacity and supporting upcoming product launches. Under the terms of the agreement, Boehringer Ingelheim will grant Sanofi access to its Biberach an der Riss capacity in Germany to allow the French company to transfer production of its monoclonal antibodies (mAbs). The product transfer will be initiated in shortest terms this year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANNV:FP €79.00 EUR +0.23

SANNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.35 USD -2.77
Amgen Inc $152.26 USD -4.11
Bristol-Myers Squibb Co $60.27 USD -0.87
GlaxoSmithKline PLC 1,467 GBp -25.50
Novo Nordisk A/S kr295.50 DKK -4.40
View Industry Companies
 

Industry Analysis

SANNV

Industry Average

Valuation SANNV Industry Range
Price/Earnings 23.9x
Price/Sales 2.9x
Price/Book 1.9x
Price/Cash Flow 14.7x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-NEW, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.